社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
dahae
IP属地：未知
+关注
帖子 · 302
帖子 · 302
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
dahae
dahae
·
2022-01-16
Q
非常抱歉，此主贴已删除
看
4,481
回复
1
点赞
点赞
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-15
Q
非常抱歉，此主贴已删除
看
4,459
回复
1
点赞
2
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-15
Qqqq
非常抱歉，此主贴已删除
看
3,777
回复
1
点赞
1
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-14
Qqq
10 Biggest Price Target Changes For Friday<blockquote>周五 10 大价格目标变化</blockquote>
Keybanc cut Robinhood Markets, Inc. price target from $50 to $25. Robinhood shares fell 0.1% to $15.
10 Biggest Price Target Changes For Friday<blockquote>周五 10 大价格目标变化</blockquote>
看
4,613
回复
1
点赞
1
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-13
Qqqq
Biogen says yet to speak with CMS about coverage of Alzheimer's drug<blockquote>百健表示尚未与 CMS 讨论阿尔茨海默氏症药物的覆盖范围</blockquote>
(Reuters) - Biogen Inc has not discussed with the Centers for Medicaid and Medicare Services about i
Biogen says yet to speak with CMS about coverage of Alzheimer's drug<blockquote>百健表示尚未与 CMS 讨论阿尔茨海默氏症药物的覆盖范围</blockquote>
看
4,148
回复
1
点赞
1
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-13
Qqq
Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal<blockquote>美容公司 Suneva 正在就 Viveon Health SPAC 交易进行谈判</blockquote>
(Bloomberg) -- Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices,
Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal<blockquote>美容公司 Suneva 正在就 Viveon Health SPAC 交易进行谈判</blockquote>
看
3,915
回复
1
点赞
点赞
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-11
Qqwq
7 Hot Stocks to Buy on Any Dip This Year<blockquote>今年逢低买入的 7 只热门股票</blockquote>
An increase in interest rates is looming due to higher inflation, supply-chain issues, lofty stock v
7 Hot Stocks to Buy on Any Dip This Year<blockquote>今年逢低买入的 7 只热门股票</blockquote>
看
5,108
回复
1
点赞
点赞
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-10
Qqqqq
Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky<blockquote>特斯拉股价将达到 1,400 美元还是 67 美元？为什么预测汽车制造商的业绩很棘手</blockquote>
Who needs parody cryptocurrency when car stocks are this exciting?
Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky<blockquote>特斯拉股价将达到 1,400 美元还是 67 美元？为什么预测汽车制造商的业绩很棘手</blockquote>
看
5,537
回复
4
点赞
6
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-10
Qqqq
The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年的前三次 IPO 都举步维艰。这就是原因。</blockquote>
The first initial public offerings of 2022, a trio of biotech companies, went public with dismal res
The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年的前三次 IPO 都举步维艰。这就是原因。</blockquote>
看
3,703
回复
1
点赞
点赞
编组 21备份 2
分享
举报
dahae
dahae
·
2022-01-08
Qqq
非常抱歉，此主贴已删除
看
3,867
回复
1
点赞
1
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3560092322694803","uuid":"3560092322694803","gmtCreate":1597135194870,"gmtModify":1614044926890,"name":"dahae","pinyin":"dahae","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":156,"tweetSize":302,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":697377494,"gmtCreate":1642326902440,"gmtModify":1642326902648,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Q","listText":"Q","text":"Q","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697377494","repostId":"1169852230","repostType":4,"isVote":1,"tweetType":1,"viewCount":4481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697943099,"gmtCreate":1642236922912,"gmtModify":1642236923082,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Q","listText":"Q","text":"Q","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697943099","repostId":"2203198710","repostType":4,"isVote":1,"tweetType":1,"viewCount":4459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697949554,"gmtCreate":1642236866890,"gmtModify":1642236867086,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqqq","listText":"Qqqq","text":"Qqqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697949554","repostId":"2203198710","repostType":4,"isVote":1,"tweetType":1,"viewCount":3777,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697066627,"gmtCreate":1642166898668,"gmtModify":1642167319572,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqq","listText":"Qqq","text":"Qqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697066627","repostId":"1159268879","repostType":4,"repost":{"id":"1159268879","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642163579,"share":"https://www.laohunote.com/m/news/1159268879?lang=zh_CN&edition=full","pubTime":"2022-01-14 20:32","market":"us","language":"en","title":"10 Biggest Price Target Changes For Friday<blockquote>周五 10 大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159268879","media":"Benzinga Earnings","summary":"Keybanc cut Robinhood Markets, Inc. price target from $50 to $25. Robinhood shares fell 0.1% to $15.","content":"<p><html><head></head><body><ul><li>Keybanc cut <b>Robinhood Markets, Inc.</b> price target from $50 to $25. Robinhood shares fell 0.1% to $15.28 in pre-market trading.</li><li>SVB Leerink boosted <b>Amicus Therapeutics, Inc.</b> price target from $12 to $16. Amicus Therapeutics shares rose 3.9% to $10.30 in pre-market trading.</li><li>JP Morgan raised the price target for <b>O'Reilly Automotive, Inc.</b> from $695 to $785. O'Reilly Automotive shares rose 1.4% to $697.15 in pre-market trading.</li><li>BMO Capital raised <b>The Mosaic Company</b> price target from $37 to $50. Mosaic shares rose 2.8% to $42.79 in pre-market trading.</li><li>RBC Capital lifted <b>Ford Motor Company</b> price target from $21 to $26. Ford shares fell 1.7% to $24.60 in pre-market trading.</li><li>Keybanc reduced the price target on <b>Zoom Video Communications, Inc.</b> from $344 to $253. Zoom Video shares fell 0.3% to $161.61 in pre-market trading.</li><li>Raymond James raised the price target for <b>KB Home</b> from $55 to $63. KB Home shares fell 0.4% to $49.20 in pre-market trading.</li><li>Keybanc reduced the price target on <b>PayPal Holdings, Inc.</b> from $325 to $250. PayPal shares fell 0.1% to $180.82 in pre-market trading.</li><li>Morgan Stanley cut <b>Domino's Pizza, Inc.</b> price target from $541 to $535. Domino's shares dropped 1.3% to $475.00 in pre-market trading.</li><li>JMP Securities boosted the price target on <b>Chubb Limited</b> from $210 to $225. Chubb shares rose 0.3% to $198.20 in pre-market trading.</li></ul></body></html></p><p><blockquote><html><head></head><body><ul><li>Keybanc 切割<b>罗宾汉市场公司。</b>目标价从50美元到25美元不等。Robinhood 股价在盘前交易中下跌 0.1%，至 15.28 美元。</li><li>SVB Leerink 增强<b>阿米库斯治疗公司。</b>目标价从12美元到16美元。Amicus Therapeutics 股价在盘前交易中上涨 3.9%，至 10.30 美元。</li><li>摩根大通上调目标价<b>奥莱利汽车公司。</b>从695美元到785美元。O'Reilly Automotive 股价在盘前交易中上涨 1.4%，至 697.15 美元。</li><li>BMO 筹集资金<b>马赛克公司</b>目标价从37美元到50美元。Mosaic 股价在盘前交易中上涨 2.8%，至 42.79 美元。</li><li>加拿大皇家银行资本解禁<b>福特汽车</b>目标价从21美元到26美元。福特股价在盘前交易中下跌 1.7%，至 24.60 美元。</li><li>Keybanc 下调目标价<b>Zoom Video通信公司。</b>从344美元到253美元。Zoom Video股价在盘前交易中下跌 0.3%，至 161.61 美元。</li><li>雷蒙德·詹姆斯上调了目标价<b>KB主页</b>从55美元到63美元。KB Home 股价在盘前交易中下跌 0.4%，至 49.20 美元。</li><li>Keybanc 下调目标价<b>PayPal控股公司。</b>从325美元到250美元。PayPal股价在盘前交易中下跌 0.1%，至 180.82 美元。</li><li>摩根士丹利削减<b>达美乐披萨公司。</b>目标价从 541 美元到 535 美元。达美乐股价在盘前交易中下跌 1.3%，至 475.00 美元。</li><li>JMP证券上调目标价<b>集宝有限公司</b>从210美元到225美元。Chubb 股价在盘前交易中上涨 0.3%，至 198.20 美元。</li></ul></body></html></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Friday<blockquote>周五 10 大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Friday<blockquote>周五 10 大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2022-01-14 20:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><ul><li>Keybanc cut <b>Robinhood Markets, Inc.</b> price target from $50 to $25. Robinhood shares fell 0.1% to $15.28 in pre-market trading.</li><li>SVB Leerink boosted <b>Amicus Therapeutics, Inc.</b> price target from $12 to $16. Amicus Therapeutics shares rose 3.9% to $10.30 in pre-market trading.</li><li>JP Morgan raised the price target for <b>O'Reilly Automotive, Inc.</b> from $695 to $785. O'Reilly Automotive shares rose 1.4% to $697.15 in pre-market trading.</li><li>BMO Capital raised <b>The Mosaic Company</b> price target from $37 to $50. Mosaic shares rose 2.8% to $42.79 in pre-market trading.</li><li>RBC Capital lifted <b>Ford Motor Company</b> price target from $21 to $26. Ford shares fell 1.7% to $24.60 in pre-market trading.</li><li>Keybanc reduced the price target on <b>Zoom Video Communications, Inc.</b> from $344 to $253. Zoom Video shares fell 0.3% to $161.61 in pre-market trading.</li><li>Raymond James raised the price target for <b>KB Home</b> from $55 to $63. KB Home shares fell 0.4% to $49.20 in pre-market trading.</li><li>Keybanc reduced the price target on <b>PayPal Holdings, Inc.</b> from $325 to $250. PayPal shares fell 0.1% to $180.82 in pre-market trading.</li><li>Morgan Stanley cut <b>Domino's Pizza, Inc.</b> price target from $541 to $535. Domino's shares dropped 1.3% to $475.00 in pre-market trading.</li><li>JMP Securities boosted the price target on <b>Chubb Limited</b> from $210 to $225. Chubb shares rose 0.3% to $198.20 in pre-market trading.</li></ul></body></html></p><p><blockquote><html><head></head><body><ul><li>Keybanc 切割<b>罗宾汉市场公司。</b>目标价从50美元到25美元不等。Robinhood 股价在盘前交易中下跌 0.1%，至 15.28 美元。</li><li>SVB Leerink 增强<b>阿米库斯治疗公司。</b>目标价从12美元到16美元。Amicus Therapeutics 股价在盘前交易中上涨 3.9%，至 10.30 美元。</li><li>摩根大通上调目标价<b>奥莱利汽车公司。</b>从695美元到785美元。O'Reilly Automotive 股价在盘前交易中上涨 1.4%，至 697.15 美元。</li><li>BMO 筹集资金<b>马赛克公司</b>目标价从37美元到50美元。Mosaic 股价在盘前交易中上涨 2.8%，至 42.79 美元。</li><li>加拿大皇家银行资本解禁<b>福特汽车</b>目标价从21美元到26美元。福特股价在盘前交易中下跌 1.7%，至 24.60 美元。</li><li>Keybanc 下调目标价<b>Zoom Video通信公司。</b>从344美元到253美元。Zoom Video股价在盘前交易中下跌 0.3%，至 161.61 美元。</li><li>雷蒙德·詹姆斯上调了目标价<b>KB主页</b>从55美元到63美元。KB Home 股价在盘前交易中下跌 0.4%，至 49.20 美元。</li><li>Keybanc 下调目标价<b>PayPal控股公司。</b>从325美元到250美元。PayPal股价在盘前交易中下跌 0.1%，至 180.82 美元。</li><li>摩根士丹利削减<b>达美乐披萨公司。</b>目标价从 541 美元到 535 美元。达美乐股价在盘前交易中下跌 1.3%，至 475.00 美元。</li><li>JMP证券上调目标价<b>集宝有限公司</b>从210美元到225美元。Chubb 股价在盘前交易中上涨 0.3%，至 198.20 美元。</li></ul></body></html></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FOLD":"爱美医疗","MOS":"美国美盛","DPZ":"达美乐比萨","ORLY":"奥莱利","HOOD":"Robinhood","CB":"安达保险","ZM":"Zoom","KBH":"KB Home","F":"福特汽车","PYPL":"PayPal"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159268879","content_text":"Keybanc cut Robinhood Markets, Inc. price target from $50 to $25. Robinhood shares fell 0.1% to $15.28 in pre-market trading.SVB Leerink boosted Amicus Therapeutics, Inc. price target from $12 to $16. Amicus Therapeutics shares rose 3.9% to $10.30 in pre-market trading.JP Morgan raised the price target for O'Reilly Automotive, Inc. from $695 to $785. O'Reilly Automotive shares rose 1.4% to $697.15 in pre-market trading.BMO Capital raised The Mosaic Company price target from $37 to $50. Mosaic shares rose 2.8% to $42.79 in pre-market trading.RBC Capital lifted Ford Motor Company price target from $21 to $26. Ford shares fell 1.7% to $24.60 in pre-market trading.Keybanc reduced the price target on Zoom Video Communications, Inc. from $344 to $253. Zoom Video shares fell 0.3% to $161.61 in pre-market trading.Raymond James raised the price target for KB Home from $55 to $63. KB Home shares fell 0.4% to $49.20 in pre-market trading.Keybanc reduced the price target on PayPal Holdings, Inc. from $325 to $250. PayPal shares fell 0.1% to $180.82 in pre-market trading.Morgan Stanley cut Domino's Pizza, Inc. price target from $541 to $535. Domino's shares dropped 1.3% to $475.00 in pre-market trading.JMP Securities boosted the price target on Chubb Limited from $210 to $225. Chubb shares rose 0.3% to $198.20 in pre-market trading.","news_type":1,"symbols_score_info":{"CB":0.9,"MOS":0.9,"FOLD":0.9,"HOOD":0.9,"F":0.9,"PYPL":0.9,"DPZ":0.9,"ZM":0.9,"KBH":0.9,"ORLY":0.9}},"isVote":1,"tweetType":1,"viewCount":4613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694428999,"gmtCreate":1642084303985,"gmtModify":1642084304152,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqqq","listText":"Qqqq","text":"Qqqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694428999","repostId":"2203976407","repostType":4,"repost":{"id":"2203976407","kind":"highlight","pubTimestamp":1642082123,"share":"https://www.laohunote.com/m/news/2203976407?lang=zh_CN&edition=full","pubTime":"2022-01-13 21:55","market":"us","language":"en","title":"Biogen says yet to speak with CMS about coverage of Alzheimer's drug<blockquote>百健表示尚未与 CMS 讨论阿尔茨海默氏症药物的覆盖范围</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2203976407","media":"Reuters","summary":"(Reuters) - Biogen Inc has not discussed with the Centers for Medicaid and Medicare Services about i","content":"<p><html><head></head><body>(Reuters) - Biogen Inc has not discussed with the Centers for Medicaid and Medicare Services about its decision on the coverage of the drugmaker's Alzheimer's drug, the company's chief executive officer said in a call with the analyst.</p><p><blockquote><html><head></head><body>（路透社）-百健公司首席执行官在与分析师的看涨期权上表示，该公司尚未与医疗补助和医疗保险服务中心讨论其关于该制药商阿尔茨海默氏症药物承保范围的决定。</body></html></blockquote></p><p>In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials.</p><p><blockquote>在周二的一份决定草案中，为 65 岁以上人群运营政府健康计划的 CMS 表示，它将仅为参加批准临床试验的患者承保 Aduhelm 和类似治疗。</blockquote></p><p>"We want to be constructive with CMS. We want just to have a dialogue," Biogen CEO Michel Vounatsos said.</p><p><blockquote>“我们希望与 CMS 保持建设性。我们只是想进行对话，”百健首席执行官 Michel Vounatsos 说道。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen says yet to speak with CMS about coverage of Alzheimer's drug<blockquote>百健表示尚未与 CMS 讨论阿尔茨海默氏症药物的覆盖范围</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen says yet to speak with CMS about coverage of Alzheimer's drug<blockquote>百健表示尚未与 CMS 讨论阿尔茨海默氏症药物的覆盖范围</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2022-01-13 21:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>(Reuters) - Biogen Inc has not discussed with the Centers for Medicaid and Medicare Services about its decision on the coverage of the drugmaker's Alzheimer's drug, the company's chief executive officer said in a call with the analyst.</p><p><blockquote><html><head></head><body>（路透社）-百健公司首席执行官在与分析师的看涨期权上表示，该公司尚未与医疗补助和医疗保险服务中心讨论其关于该制药商阿尔茨海默氏症药物承保范围的决定。</body></html></blockquote></p><p>In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials.</p><p><blockquote>在周二的一份决定草案中，为 65 岁以上人群运营政府健康计划的 CMS 表示，它将仅为参加批准临床试验的患者承保 Aduhelm 和类似治疗。</blockquote></p><p>"We want to be constructive with CMS. We want just to have a dialogue," Biogen CEO Michel Vounatsos said.</p><p><blockquote>“我们希望与 CMS 保持建设性。我们只是想进行对话，”百健首席执行官 Michel Vounatsos 说道。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMS":"CMS能源","BK4139":"生物科技","BK4208":"复合型公用事业","BIIB":"渤健公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4532":"文艺复兴科技持仓"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203976407","content_text":"(Reuters) - Biogen Inc has not discussed with the Centers for Medicaid and Medicare Services about its decision on the coverage of the drugmaker's Alzheimer's drug, the company's chief executive officer said in a call with the analyst.In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials.\"We want to be constructive with CMS. We want just to have a dialogue,\" Biogen CEO Michel Vounatsos said.","news_type":1,"symbols_score_info":{"CMS":1,"BIIB":1}},"isVote":1,"tweetType":1,"viewCount":4148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694257889,"gmtCreate":1642003502104,"gmtModify":1642003502285,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqq","listText":"Qqq","text":"Qqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694257889","repostId":"1199219279","repostType":4,"repost":{"id":"1199219279","kind":"news","pubTimestamp":1641998773,"share":"https://www.laohunote.com/m/news/1199219279?lang=zh_CN&edition=full","pubTime":"2022-01-12 22:46","market":"us","language":"en","title":"Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal<blockquote>美容公司 Suneva 正在就 Viveon Health SPAC 交易进行谈判</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199219279","media":"Bloomberg","summary":"(Bloomberg) -- Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices, ","content":"<p><html><head></head><body>(Bloomberg) -- Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices, has agreed to go public through a merger with blank-check company Viveon Health Acquisition Corp.</p><p><blockquote><html><head></head><body>(彭博社）--向医生办公室销售美容和抗衰老产品的 Suneva Medical Inc.已同意通过与空白支票公司 Viveon Health Acquisition Corp. 合并上市。</body></html></blockquote></p><p>The deal values the combined company at about $511 million including debt, according to a statement Wednesday that confirmed an earlier Bloomberg News report. Existing Suneva backers will invest $10 million in a private investment in public equity deal, according to Chief Executive Officer Pat Altavilla.</p><p><blockquote>根据周三发布的一份声明，该交易对合并后的公司（包括债务）的估值约为 5.11 亿美元，该声明证实了彭博新闻社早些时候的报道。首席执行官帕特·阿尔塔维拉 (Pat Altavilla) 表示，现有的 Suneva 支持者将在公共股权交易中投资 1000 万美元进行私人投资。</blockquote></p><p>The combined company will operate as Suneva Medical and trade on the New York Stock Exchange under the symbol RNEW, according to the statement.</p><p><blockquote>声明称，合并后的公司将以 Suneva Medical 的名义运营，并在纽约证券交易所上市，股票代码为 RNEW。</blockquote></p><p>“It’s a wonderful way for Suneva to become fully capitalized to take advantage of the remarkable capabilities of the capital markets and to grow the business the way we intend to,” Altavilla said in an interview.</p><p><blockquote>“阿尔塔维拉在接受采访时说：”对于 Suneva 来说，这是一个很好的方式，可以充分利用资本市场的卓越能力，并按照我们的预期发展业务。</blockquote></p><p>Suneva expects to grow by developing new products like a hair-restoration offering, acquiring businesses and catering to more men and millenials, she said.</p><p><blockquote>她说，Suneva希望通过开发头发修复产品等新产品、收购业务以及迎合更多男性和千禧一代来实现增长。</blockquote></p><p>Suneva specializes in so-called regenerative aesthetics that use the body’s own collagen to improve the skin’s appearance. Its biggest product is Bellafill, a Food and Drug Administration-approved dermal filler that is advertised to “smooth smile lines” and reduce the appearance of acne scars. Its products and procedures, all of which Altavilla said have a “biostimulatory component” are sold into medical offices and conducted by doctors, nurses or nurse practitioners. It has about 1600 customers, she said.</p><p><blockquote>Suneva 专注于所谓的再生美容，即利用人体自身的胶原蛋白改善皮肤外观。其最大的产品是 Bellafill，这是一种经美国食品和药物管理局批准的真皮填充剂，广告宣传可以 “抚平笑纹 ”并减少痤疮疤痕的出现。Altavilla 称其产品和程序都含有 “生物刺激成分”，这些产品和程序都销往医疗机构，由医生、护士或执业护士进行。她说，它有大约1600名顾客。</blockquote></p><p>Viveon Health Acquisition, a special purpose acquisition company, or SPAC, raised $201 million in its initial public offering in 2020.</p><p><blockquote>Viveon Health Acquisition 是一家特殊目的收购公司 (SPAC)，在 2020 年的首次公开募股中筹集了 2.01 亿美元。</blockquote></p><p>“People are looking toward more natural solutions,” Altavilla said. “The regenerative properties of these procedures allow them to have better longer-lasting results.”</p><p><blockquote>“阿尔塔维拉说：”人们正在寻找更自然的解决方案。“这些手术的再生特性使其具有更好、更持久的效果”。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal<blockquote>美容公司 Suneva 正在就 Viveon Health SPAC 交易进行谈判</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal<blockquote>美容公司 Suneva 正在就 Viveon Health SPAC 交易进行谈判</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2022-01-12 22:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>(Bloomberg) -- Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices, has agreed to go public through a merger with blank-check company Viveon Health Acquisition Corp.</p><p><blockquote><html><head></head><body>(彭博社）--向医生办公室销售美容和抗衰老产品的 Suneva Medical Inc.已同意通过与空白支票公司 Viveon Health Acquisition Corp. 合并上市。</body></html></blockquote></p><p>The deal values the combined company at about $511 million including debt, according to a statement Wednesday that confirmed an earlier Bloomberg News report. Existing Suneva backers will invest $10 million in a private investment in public equity deal, according to Chief Executive Officer Pat Altavilla.</p><p><blockquote>根据周三发布的一份声明，该交易对合并后的公司（包括债务）的估值约为 5.11 亿美元，该声明证实了彭博新闻社早些时候的报道。首席执行官帕特·阿尔塔维拉 (Pat Altavilla) 表示，现有的 Suneva 支持者将在公共股权交易中投资 1000 万美元进行私人投资。</blockquote></p><p>The combined company will operate as Suneva Medical and trade on the New York Stock Exchange under the symbol RNEW, according to the statement.</p><p><blockquote>声明称，合并后的公司将以 Suneva Medical 的名义运营，并在纽约证券交易所上市，股票代码为 RNEW。</blockquote></p><p>“It’s a wonderful way for Suneva to become fully capitalized to take advantage of the remarkable capabilities of the capital markets and to grow the business the way we intend to,” Altavilla said in an interview.</p><p><blockquote>“阿尔塔维拉在接受采访时说：”对于 Suneva 来说，这是一个很好的方式，可以充分利用资本市场的卓越能力，并按照我们的预期发展业务。</blockquote></p><p>Suneva expects to grow by developing new products like a hair-restoration offering, acquiring businesses and catering to more men and millenials, she said.</p><p><blockquote>她说，Suneva希望通过开发头发修复产品等新产品、收购业务以及迎合更多男性和千禧一代来实现增长。</blockquote></p><p>Suneva specializes in so-called regenerative aesthetics that use the body’s own collagen to improve the skin’s appearance. Its biggest product is Bellafill, a Food and Drug Administration-approved dermal filler that is advertised to “smooth smile lines” and reduce the appearance of acne scars. Its products and procedures, all of which Altavilla said have a “biostimulatory component” are sold into medical offices and conducted by doctors, nurses or nurse practitioners. It has about 1600 customers, she said.</p><p><blockquote>Suneva 专注于所谓的再生美容，即利用人体自身的胶原蛋白改善皮肤外观。其最大的产品是 Bellafill，这是一种经美国食品和药物管理局批准的真皮填充剂，广告宣传可以 “抚平笑纹 ”并减少痤疮疤痕的出现。Altavilla 称其产品和程序都含有 “生物刺激成分”，这些产品和程序都销往医疗机构，由医生、护士或执业护士进行。她说，它有大约1600名顾客。</blockquote></p><p>Viveon Health Acquisition, a special purpose acquisition company, or SPAC, raised $201 million in its initial public offering in 2020.</p><p><blockquote>Viveon Health Acquisition 是一家特殊目的收购公司 (SPAC)，在 2020 年的首次公开募股中筹集了 2.01 亿美元。</blockquote></p><p>“People are looking toward more natural solutions,” Altavilla said. “The regenerative properties of these procedures allow them to have better longer-lasting results.”</p><p><blockquote>“阿尔塔维拉说：”人们正在寻找更自然的解决方案。“这些手术的再生特性使其具有更好、更持久的效果”。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/aesthetics-firm-suneva-said-talks-010000738.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VHAQ":"Viveon Health Acquisition Corp"},"source_url":"https://finance.yahoo.com/news/aesthetics-firm-suneva-said-talks-010000738.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199219279","content_text":"(Bloomberg) -- Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices, has agreed to go public through a merger with blank-check company Viveon Health Acquisition Corp.The deal values the combined company at about $511 million including debt, according to a statement Wednesday that confirmed an earlier Bloomberg News report. Existing Suneva backers will invest $10 million in a private investment in public equity deal, according to Chief Executive Officer Pat Altavilla.The combined company will operate as Suneva Medical and trade on the New York Stock Exchange under the symbol RNEW, according to the statement.“It’s a wonderful way for Suneva to become fully capitalized to take advantage of the remarkable capabilities of the capital markets and to grow the business the way we intend to,” Altavilla said in an interview.Suneva expects to grow by developing new products like a hair-restoration offering, acquiring businesses and catering to more men and millenials, she said.Suneva specializes in so-called regenerative aesthetics that use the body’s own collagen to improve the skin’s appearance. Its biggest product is Bellafill, a Food and Drug Administration-approved dermal filler that is advertised to “smooth smile lines” and reduce the appearance of acne scars. Its products and procedures, all of which Altavilla said have a “biostimulatory component” are sold into medical offices and conducted by doctors, nurses or nurse practitioners. It has about 1600 customers, she said.Viveon Health Acquisition, a special purpose acquisition company, or SPAC, raised $201 million in its initial public offering in 2020.“People are looking toward more natural solutions,” Altavilla said. “The regenerative properties of these procedures allow them to have better longer-lasting results.”","news_type":1,"symbols_score_info":{"VHAQ":0.9}},"isVote":1,"tweetType":1,"viewCount":3915,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694127230,"gmtCreate":1641875151933,"gmtModify":1641875152131,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqwq","listText":"Qqwq","text":"Qqwq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694127230","repostId":"1104925214","repostType":4,"repost":{"id":"1104925214","kind":"news","pubTimestamp":1641868694,"share":"https://www.laohunote.com/m/news/1104925214?lang=zh_CN&edition=full","pubTime":"2022-01-11 10:38","market":"us","language":"en","title":"7 Hot Stocks to Buy on Any Dip This Year<blockquote>今年逢低买入的 7 只热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104925214","media":"InvestorPlace","summary":"An increase in interest rates is looming due to higher inflation, supply-chain issues, lofty stock v","content":"<p><div> An increase in interest rates is looming due to higher inflation, supply-chain issues, lofty stock valuations and now the super-contagious omicron variant of Covid-19. As a result, forecasting market ...</p><p><blockquote><div>由于通胀上升、供应链问题、高股票估值以及现在具有超强传染性的 Covid-19 奥密克戎变种，利率上升迫在眉睫。因此，预测市场……</div></blockquote></p><p> <a href=\"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Hot Stocks to Buy on Any Dip This Year<blockquote>今年逢低买入的 7 只热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Hot Stocks to Buy on Any Dip This Year<blockquote>今年逢低买入的 7 只热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2022-01-11 10:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> An increase in interest rates is looming due to higher inflation, supply-chain issues, lofty stock valuations and now the super-contagious omicron variant of Covid-19. As a result, forecasting market ...</p><p><blockquote><div>由于通胀上升、供应链问题、高股票估值以及现在具有超强传染性的 Covid-19 奥密克戎变种，利率上升迫在眉睫。因此，预测市场……</div></blockquote></p><p> <a href=\"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","SCHW":"嘉信理财","UMI":"USCF Midstream Energy Income Fund","ADI":"亚德诺","FSR":"菲斯克","DD":"杜邦","ADMT":"ADM Tronics Unlimited, Inc."},"source_url":"https://investorplace.com/2022/01/7-hot-stocks-to-buy-on-any-dip-this-year/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104925214","content_text":"An increase in interest rates is looming due to higher inflation, supply-chain issues, lofty stock valuations and now the super-contagious omicron variant of Covid-19. As a result, forecasting market performance for 2022 seems more difficult than it’s been in previous years. Right now, it looks like the market is priced to perfection with a slim margin of error. Therefore, investors could benefit by keeping an eye on hot stocks.Since March 2020, the bull market has seen returns of nearly 110% in the S&P 500Index. Despite such a remarkable rally, we need to highlight that 93% of the index saw a selloff of more than 10% in 2021.While Wells Fargo predicts that the S&P 500 index could hit 5,300, Morgan Stanley has a bearish outlook with a year-end 2022 target for 4,400. That suggest a decline of more than 4% from current levels.Amidst so much uncertainty, market analysts have expressed conflicting opinions about where investor gains in the new year may come from. Market forecasts for 2022 might ultimately rely on correctly forecasting how the pandemic evolves. “The pathof the economy continues to depend on the course of the virus,” the Federal Open Market Committee’s stated following the Federal Reserve meeting in December.With that information, here are seven hot stocks that offer substantial upside to any investor portfolio in 2022:Analog Devices(NASDAQ:ADI)Applied Materials(NASDAQ:AMAT)Charles Schwab(NYSE:SCHW)Dupont De Nemours (NYSE:DD)Fisker (NYSE:FSR)Unity Software(NYSE:U)USCF Midstream Energy Income Fund(NYSEARCA:UMI)Hot Stocks: Analog Devices(ADI)52-week range:$142.25 – $191.95Dividend yield:1.6%Leading our list of hot stocks to watch is Wilmington, Massachusetts-based Analog Devices. The company manufactures chips that leverage high-performance analog, mixed-signal and digital signal processing technology. The chipmaker has a leading market share in converter chips that translate analog signals to digital and vice versa.Analog Devices announced fourth-quarter 2021 results on Nov. 23, 2021. Revenue increased 53% year-over-year (YOY) to $2.34 billion. Adjusted earnings increased from $1.44 per share to $1.73 per share. The chipmaker generated a free cash flow of $810 million during the period. Cash and equivalents ended the quarter at $1.98 billion.On the metrics, CEO Vincent Roche said, “ADI delivered another quarter of record revenue and profits, marking a strong end to the fiscal year. Our Industrial and Automotive markets reached all-time highs and our Consumer business returned to solid growth in fiscal 2021.”The chipmaker continues to expand its manufacturing capacity to meet the rising demand for its cutting-edge chips. In fact, Analog received more orders than it could fill during the past year, leading to a solid backlog for its products. Moreover, it has recently completed the acquisition of Maxim Integrated, further solidifying its position as a semiconductor leader.Most of Analog’s revenue comes from the industrial and automotive markets. Factory automation is driving surging demand for sensors and connectivity options for machines, all of which require the use of ADI’s chips. Furthermore, the automotive industry’s demand for chips continues to grow rapidly due to the increasing popularity of electric vehicles(EVs).Currently, ADI stock hovers just below $170 per share, up nearly 8% over the past 12 months. Shares are trading at 24 times forward earnings and 10 times trailing sales. The 12-month median price forecast for Analog Devicesstands at $210.Applied Materials(AMAT)52-week range:$94.18 – $163.02Dividend yield:0.6%When it comes to semiconductor manufacturing equipment, the one company that tops the list is the Santa Clara, California-based Applied Materials. It iswell-known for materials and engineering solutions.Applied Materials released Q4 2021 results in mid-November. It reported a record quarterly revenue of $6.12 billion, up 31% YOY. Adjusted net income came in at $1.76 billion, or $1.94 per diluted share, up 53% YOY from $1.15 billion, or $1.25 per diluted share, in the prior-year quarter.“Applied delivered strong growth in fiscal 2021, with overall orders up by 62 percent year over year and Semiconductor Systems orders up 78 percent,” remarked CFO Bob Halliday. “The momentum continued as our Semiconductor Systems backlog increased during the fourth quarter from $5.5 billion to $6.7 billion, and we see this strength sustaining into 2022.”The company stands to benefit from crucial high-growth trends, including artificial intelligence, 5G, cloud computing, the Internet of Things (IoT) and autonomous driving. In particular, Applied Materials continues to gain significant market share in process control, including wafer inspection and e-beam technology. Demand for these services should keep AMAT on your list of hot stocks to watch.In addition, Applied Materials plays a vital role in the U.S. tech industry. The lion’s share of global chip manufacturing is based in Taiwan, so the U.S. and Europe are looking to expand their domestic chip manufacturing capabilities. This implies significant long-term growth opportunities for equipment suppliers like Applied Materials.At present, AMAT stock is priced around $145. Over the past 12 months, it has surged 53%. Given the rising global demand for foundry and logic capacity, the company has a moderate valuation at 18.7 times forward earnings and 6.1 times trailing sales. The 12-month median price forecast for Applied Materials stock stands at $174.Hot Stocks: Charles Schwab(SCHW)52-week range:$50.77 – $92.32Dividend yield:0.8%In addition to brokerage services, the San Francisco, California-based Charles Schwab offers asset management, wealth management, banking, and other financial advisory services. Currently,the group boasts about $8 trillion in client assets, nearly 33 million active brokerage accounts and more than 2 million corporate retirement plan participants.Charles Schwab released Q3 2021 results in mid-October. Revenue surged 87% YOY to $4.57 billion. Further, adjusted net income grew 130% to $1.72 billion, or 84 cents per diluted share, up from $749 million, or 51 cents per diluted share, a year ago.On the results, CEO Walt Bettinger remarked, “We generated core net new assets of $139.0 billion in the quarter, pushing asset gathering for the first nine months of the year to $396.0 billion, representing an 8% annualized organic growth rate. Total client assets ended September at $7.61 trillion, up from $6.69 trillion at year-end 2020.”In 2021, the increase in assets contributed to high growth. Now Wall Street concurs that Schwab should benefit from rising interest rates in 2022. Net interest revenue accounted for around 45% of total revenue in Q3.Considering the anticipated increase in interest rates and Schwab’s powerful organic growth potential, many investors are following SCHW stock closely. It currently hovers in $90 territory, and over the past 12 months, the stock price has jumped 54%. SCHW is trading at 23.3 times forward earnings and 8.5 times trailing sales. The 12-month median price forecast for Charles Schwab stock stands at $95.50.Dupont De Nemours (DD)52-week range:$66.37 – $87.27Dividend yield:1.44%DuPont de Nemours is one of the largest chemical and specialty materials companies worldwide. It provides many synthetic components that serve automotive, electronics, construction, safety and water management industries.The company released Q3 2021 results in early November. Revenue for the period totaled $4.3 billion, up 18% YOY. Net income stood at $391 million, or 75 cents per diluted share, compared to a net loss of $79 million, or a loss of 11 cents loss per diluted share, in the prior-year quarter. Dupont generated a free cash flow of $634 million during the quarter. Cash and equivalents ended the quarter at $1.67 billion.DuPont is going through a transition period, shifting its focus from low-margin chemical businesses to higher-margin opportunities in sectors with long-term growth potential. In November, management announced the acquisitionofRogers Corporation for $5.2 billion.This acquisition allows DuPont to gain exposure to secular high-growth markets, including electric vehicles, 5G and clean energy. Meanwhile, DuPont plans to divest most of its Mobility & Materials segment, including engineering polymers and performance resins products lines.On the acquisition, CEO Ed Breen remarked, “Today we also separately announced a definitive agreement to acquire Rogers Corporation, an advanced materials provider with superior technology innovation, applications engineering expertise, and leading end-market positions.”DD stock is currently priced just below $82 per share, up 2% in the past 12 months. Shares are trading at 16.5 times forward earnings and 2.2 times trailing sales. The 12-month median price forecast for DuPont stock stands at $96.Hot Stocks: Fisker (FSR)52-week range:$9.61 – $31.96Manhattan Beach, California-based Fisker is a pre-revenue EV name that made its market debut in 2020. It has a unique asset-light business model based on contract manufacturing.Fisker released Q3 2021 results in early November. Net loss for the period totaled $110 million, or a loss of 37 cents per share, compared to a net loss of $40 million in the previous year. Cash and equivalents ended the quarter at $1.4 billion.After the announcement, CEO Henrik Fisker noted, “We continued to make rapid progress in Q3 2021 on our core focus, achieving program milestones that ensure we execute Fisker Ocean SUV on-time and with several segment-leading features.”Production for the Fisker Ocean, a mid-size premium SUV, is set to begin in November. The EV will be available to consumers through a leasing package that costs $37,499, making it one of the most affordable EVs on the market. Fisker Ocean reservations are expected to increase in 2022 with the opening of experience centers.The Ocean is sold exclusively through the Fisker app or website without a dealer network. As a result, Wall Street is interested in its low overhead costs. Further, contract manufacturing should allow the company to enhance its EV portfolio without investing in risky manufacturing capacity.Understandably, without revenues, Fisker is a speculative EV play. FSR stock hovers in $15 territory, up 2% over the past year. The 12-month median price forecast for Fisker stock stands at $25.50.Unity Software(U)52-week range:$76 – $210Unity Software offers a software platform for developing interactive experiences and creating computer-generated visuals. The company is well-known for providing an engine for video games that work across computers, consoles, smart phones and virtual reality (VR) devices.Unity reported Q3 2021 results in early November. Revenue soared 43% YOY to $286 million. But non-GAAP loss widened to $12.1 million, or 6 cents per diluted share, compared to a loss of $8.4 million, or 9 cents per diluted share, in the previous year. Cash and equivalents ended the period at $755 million.On the results, CEO John Riccitiello remarked, “Unity’s strong performance this quarter was driven by innovation in data science, vertical growth and making significant strides in bringing RT3D technologies and tools to as many creators and artists as possible.”Wall Street agrees Unity should benefit from the development of the metaverse. It is swiftly gaining a solid foothold in the VR and augmented reality (AR) markets. Around 60% of all games built for AR and VR are currently utilizing its engine services.Moreover, Unity has recently acquired the visual-effects studioWeta Digital. This new business could soon enable the company to offer digital-effects services for film, games and television.Unity hit an all-time high of $210 in mid-November. However, it currently trades around $125, down 13% over the past year. Shares are trading at 39x trailing sales. The 12-month median price forecast for Unity stock stands at $185.Hot Stocks: USCF Midstream Energy Income Fund(UMI)52-Week Range: $24.32 – $32.62Expense Ratio: 0.85% per yearClosing out this list of hot stocks to monitor is the USCF Midstream Energy Income Fund, an exchange-traded fund (ETF).It invests in U.S. and Canadian midstream energy companies, including master limited partnerships (MLPs). These energy infrastructure companies focus on transportation, storage, gathering and processing of energy.UMI, which started trading in March 2021, has24 holdings. Fund managers choose companies based on their income growth, balance sheet strength, distribution (or dividend) coverage and contract quality. Exposure to commodity prices is also important as it can impact share prices, especially in the short run.The top 10 names account for around 65% of net assets of $125.2 million. Among the leading names on the roster are Targa Resources(NYSE:TRGP),Enbridge(NYSE:ENB) and Enterprise Products Partners(NYSE:EPD).Robust MLPs with quality contracts and solid fundamental metrics tend to be cash cows that most investors love. Since its inception in March 2020, UMI has soared more than 20% and saw a record high of $32.62 in mid-October. Interested investors should consider buying at $28.50.","news_type":1,"symbols_score_info":{"ADI":0.9,"DD":0.9,"U":0.9,"ADMT":0.9,"SCHW":0.9,"UMI":0.9,"FSR":0.9}},"isVote":1,"tweetType":1,"viewCount":5108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694391913,"gmtCreate":1641806328163,"gmtModify":1641806328363,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqqqq","listText":"Qqqqq","text":"Qqqqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/694391913","repostId":"1199490797","repostType":4,"repost":{"id":"1199490797","kind":"news","pubTimestamp":1641828722,"share":"https://www.laohunote.com/m/news/1199490797?lang=zh_CN&edition=full","pubTime":"2022-01-10 23:32","market":"us","language":"en","title":"Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky<blockquote>特斯拉股价将达到 1,400 美元还是 67 美元？为什么预测汽车制造商的业绩很棘手</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199490797","media":"Barrons","summary":"Who needs parody cryptocurrency when car stocks are this exciting?","content":"<p><html><head></head><body>Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the year. This, after some heady gains for the group last year.</p><p><blockquote><html><head></head><body>当汽车股如此令人兴奋时，谁还需要模仿加密货币？福特汽车公司、通用汽车公司、特斯拉公司和Rivian公司在今年第一个交易周的价格波动均超过 10%。这是在该集团去年取得一些令人兴奋的收益之后。</body></html></blockquote></p><p>Predicting performance from here won’t be easy. I recently spoke with one analyst who says Tesla stock (ticker: TSLA) is headed to $1,400, and another who says $67. You know what they say: Sometimes you have to agree to disagree by a factor of 20.</p><p><blockquote>从这里预测性能并不容易。我最近与一位分析师交谈过，他表示特斯拉股票（股票代码：TSLA）将达到 1,400 美元，另一位分析师表示将达到 67 美元。你知道他们说什么：有时候你必须同意20倍的不同意见。</blockquote></p><p>Tesla made the first big move, jumping 13.5% on Monday after the company reported fourth-quarter deliveries of 308,600 vehicles, trouncing estimates and its own record. Next, Ford (F) gained 11.7% on Tuesday after it announced that it would raise production of its first electric pickup, the F-150 Lightning, to 150,000 units a year.</p><p><blockquote>特斯拉公布第四季度交付量为 308,600 辆，超出预期和自身纪录，周一股价上涨 13.5%。接下来，福特 (F) 周二上涨 11.7%，此前该公司宣布将其首款电动皮卡 F-150 Lightning 的产量提高到每年 15 万辆。</blockquote></p><p>By that point in the week, General Motors stock (GM) was already up 12% in anticipation of its Chevy Silverado electric pickup truck unveiling, planned for Wednesday at the Consumer Electronics Show. But on the day of the announcement, shares slipped. Maybe investors were disappointed in the delivery timing, or maybe it was because the broad market tanked on signs that interest rates could rise sooner than expected.</p><p><blockquote>本周那个时候，通用汽车 (GM) 的股价已经上涨了 12%，预计其雪佛兰索罗德电动皮卡车将于周三在消费电子展上亮相。但在公告发布当天，股价下跌。也许投资者对交割时间感到失望，或者也许是因为大盘因利率可能比预期更早上升的迹象而下跌。</blockquote></p><p>What the Ford and Chevy pickups have in common is that they will target workers as well as suburban preeners in unblemished Carhartt jackets. Early versions will be priced around $40,000 and $100,000.</p><p><blockquote>福特和雪佛兰皮卡的共同点是，它们将瞄准穿着完美无瑕的卡哈特夹克的工人和郊区创业者。早期版本的价格将在4万美元和10万美元左右。</blockquote></p><p>The Chevy wins on electric specs—longer battery range and faster charging. But Ford wins on bringing its truck to market this spring. Chevy buyers will have to wait until spring 2023 for the cheaper truck and fall 2023 for the decked-out one. GM will also debut electric Chevy sport utility vehicles in 2023, including an Equinox that will start at $30,000.</p><p><blockquote>雪佛兰在电动规格上获胜——更长的电池续航里程和更快的充电速度。但福特在今年春天将其卡车推向市场方面取得了胜利。雪佛兰买家必须等到 2023 年春季才能买到更便宜的卡车，2023 年秋季才能买到装饰精美的卡车。通用汽车还将于 2023 年推出电动雪佛兰运动型多功能车，其中包括起售价为 30,000 美元的 Equinox。</blockquote></p><p>Pickup trucks could be the key to America’s electric-vehicle uptake. Last year, EVs hit an estimated 4% of total U.S. sales, up from 2%. But Europe and China are well ahead, with penetration rates in the low teens. Americans have so far had few electric choices for the types of vehicles they like to buy. Last year, the Ford F-150 led U.S. new-vehicle sales, as always. The only surprise was that the Ram 1500 pickup pulled ahead of the Chevy Silverado 1500 to be No. 2.</p><p><blockquote>皮卡车可能是美国电动汽车普及的关键。去年，电动汽车估计占美国总销量的 4%，高于 2%。但欧洲和中国遥遥领先，渗透率仅为十几岁。到目前为止，美国人对于他们喜欢购买的车辆类型几乎没有电动选择。去年，福特 F-150 一如既往地引领美国新车销量。唯一令人惊讶的是，Ram 1500 皮卡领先于雪佛兰索罗德 1500，位居第二。</blockquote></p><p>An electric Ram will take until 2024, according to owner Stellantis (STLA), a roll-up of American, Italian, and French brands. Start-up Rivian (RIVN) says it will ship electric pickups this year, but that stock slid 11% this past Wednesday after early backer Amazon.com (AMZN) said it’s putting in an order with Ram for delivery trucks. Tesla’s Cybertruck was expected last year, but has been delayed.</p><p><blockquote>据所有者 Stellantis (STLA) 称，电动 Ram 要到 2024 年才会问世，该公司是美国、意大利和法国品牌的综合体。初创公司Rivian（RIVN）表示，今年将出货电动皮卡，但上周三，在早期支持者亚马逊（AMZN）表示将向 Ram 订购送货卡车后，该公司股价下跌了 11%。特斯拉的 Cybertruck 去年就已上市，但已被推迟。</blockquote></p><p>Pent-up vehicle demand, meanwhile, suggests that a boom is coming. Amid shortages last year, U.S. light-vehicle sales were an estimated 15.1 million units, versus closer to 17 million a year before the pandemic. Average transaction prices have soared 30% from prepandemic levels, and incentives as a percentage of prices are at record lows.</p><p><blockquote>与此同时，被压抑的汽车需求表明繁荣即将到来。由于去年出现短缺，美国轻型汽车销量估计为 1510 万辆，而疫情爆发前每年接近 1700 万辆。平均交易价格已比大流行前的水平飙升了 30%，激励措施占价格的百分比也处于历史低位。</blockquote></p><p>This year, expect unit sales to rise only modestly, but by next year, when showrooms are full and pricing has eased, units could jump to 18 million, Credit Suisse says. EV penetration in the U.S. will double again this year to 8%, and top 50% by 2030, it adds.</p><p><blockquote>瑞士信贷表示，今年预计销量只会小幅增长，但到明年，当展厅爆满且定价放缓时，销量可能会跃升至 1800 万辆。它补充说，美国的电动汽车渗透率今年将再次翻一番，达到 8%，到 2030 年将达到 50%。</blockquote></p><p>One risk for legacy car makers is that they will run to stand still—that they must ramp up EV units with low profit margins for now to offset coming losses in high-margin gasoline models.</p><p><blockquote>传统汽车制造商面临的一个风险是，他们将停滞不前——他们目前必须增加利润率较低的电动汽车，以抵消高利润率汽油车型即将出现的损失。</blockquote></p><p>On the other hand, car makers could shift capacity from gasoline vehicles to electric ones ahead of customers’ willingness to make the switch. That could leave gas vehicles with high prices and profit margins, creating a long, lucrative “farewell tour,” as Morgan Stanley analyst Adam Jonas puts it.</p><p><blockquote>另一方面，汽车制造商可以在客户愿意转向电动汽车之前，将产能从汽油车转移到电动汽车。正如摩根士丹利（Morgan Stanley）分析师亚当-乔纳斯（Adam Jonas）所说，这可能会使汽油车的价格和利润率居高不下，从而造成一段漫长而利润丰厚的 “告别之旅”。</blockquote></p><p>Valuations appear undemanding. Ford goes for 12 times projected earnings, despite doubling in price last year. GM sells for nine times.</p><p><blockquote>估值似乎要求不高。尽管去年的价格翻了一番，但福特的盈利仍是预期的 12 倍。通用汽车的销量是原来的九倍。</blockquote></p><p>The bull case on Tesla is that it will do big things in both cars and adjacent markets. Philippe Houchois, who covers the stock for Jefferies, sees 35% upside from recent levels, to $1,400. Tesla lags behind legacy rivals on things like build quality and finish, but those are solvable problems, he says. It leads on software, batteries, and autonomy, which are durable advantages. He sees Tesla using software to extend the usefulness and profit potential of vehicles.</p><p><blockquote>特斯拉的看涨理由是，它将在汽车和邻近市场大展身手。杰富瑞 (Jefferies) 负责该股的 Philippe Houchois 认为，该股较近期水平上涨 35%，至 1,400 美元。他说，特斯拉在制造质量和表面处理等方面落后于传统竞争对手，但这些都是可以解决的问题。它在软件、电池和自主性方面处于领先地位，这些都是持久的优势。他认为特斯拉正在利用软件来扩展车辆的实用性和利润潜力。</blockquote></p><p>Most versions of the Tesla bear case assume that the company will do well in cars, but not well enough to justify a market value above $1 trillion. For example, J.P. Morgan’s Ryan Brinkman calls his price target of $295 “not ungenerous,” even though it implies a 70% stock plunge, because it values Tesla slightly ahead of world leader Toyota Motor (TM), despite producing a tenth as many cars for now.</p><p><blockquote>大多数版本的特斯拉贝尔案例都假设该公司在汽车领域会表现出色，但还不足以证明其超过 1 万亿美元的市值是合理的。例如，摩根大通（J.P. Morgan）的 Ryan Brinkman 评级，他将 295 美元的目标价定为 “并不慷慨”，尽管这意味着股价将暴跌 70%，因为特斯拉的估值略高于世界领先的丰田汽车（TM），尽管丰田汽车目前的产量只有丰田汽车的十分之一。</blockquote></p><p></p><p>Then there’s Gordon Johnson. He worked at large investment banks before starting GLJ Research, where he covers 20 stocks. He’s bullish on uranium stocks and bearish on cannabis, but all anyone wants to talk about, he says, is his $67 price target on Tesla. “I’ve gotten death threats,” he says. “Now I don’t even answer the phone when I have unknown calls.”</p><p><blockquote>然后是戈登-约翰逊。在开始 GLJ Research 之前，他曾在大型投资银行工作，在那里他研究了 20 只股票。他看好铀股，看跌大麻，但他说，大家只想谈论他对特斯拉的 67 美元目标价。“他说：”我收到了死亡威胁。“现在，当我有未知评级时，我甚至不接电话。”</blockquote></p><p>In Johnson’s view, there’s no reason to assume Tesla will do well in adjacent businesses. “You could take McDonald’s and say they’re going to start selling Nikes and chairs and pianos and add those valuations,” he says. In cars, he calculates that the stock price implies a production ramp-up that no car maker could achieve. “Selling cars is not selling iPhones or shirts,” he says.</p><p><blockquote>在约翰逊看来，没有理由认为特斯拉会在邻近业务中表现出色。“他说：”你可以拿麦当劳来说，他们将开始销售耐克鞋、椅子和钢琴，然后增加这些估值。在汽车方面，他计算出股价意味着任何汽车制造商都无法实现的产量增长。“他说：”卖车不是卖 iPhone 或衬衫。</blockquote></p><p>If Tesla’s three-year stock gain of nearly 1,400% has shaken Johnson’s confidence, it doesn’t show. After walking me through his valuation model, he said he’s concerned that his price target might be too high.</p><p><blockquote>如果说特斯拉三年内近 1400% 的股价涨幅动摇了约翰逊的信心，那么约翰逊的信心并没有显现出来。在向我介绍了他的估值模型后，他说他担心他的目标价可能太高。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky<blockquote>特斯拉股价将达到 1,400 美元还是 67 美元？为什么预测汽车制造商的业绩很棘手</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky<blockquote>特斯拉股价将达到 1,400 美元还是 67 美元？为什么预测汽车制造商的业绩很棘手</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2022-01-10 23:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the year. This, after some heady gains for the group last year.</p><p><blockquote><html><head></head><body>当汽车股如此令人兴奋时，谁还需要模仿加密货币？福特汽车公司、通用汽车公司、特斯拉公司和Rivian公司在今年第一个交易周的价格波动均超过 10%。这是在该集团去年取得一些令人兴奋的收益之后。</body></html></blockquote></p><p>Predicting performance from here won’t be easy. I recently spoke with one analyst who says Tesla stock (ticker: TSLA) is headed to $1,400, and another who says $67. You know what they say: Sometimes you have to agree to disagree by a factor of 20.</p><p><blockquote>从这里预测性能并不容易。我最近与一位分析师交谈过，他表示特斯拉股票（股票代码：TSLA）将达到 1,400 美元，另一位分析师表示将达到 67 美元。你知道他们说什么：有时候你必须同意20倍的不同意见。</blockquote></p><p>Tesla made the first big move, jumping 13.5% on Monday after the company reported fourth-quarter deliveries of 308,600 vehicles, trouncing estimates and its own record. Next, Ford (F) gained 11.7% on Tuesday after it announced that it would raise production of its first electric pickup, the F-150 Lightning, to 150,000 units a year.</p><p><blockquote>特斯拉公布第四季度交付量为 308,600 辆，超出预期和自身纪录，周一股价上涨 13.5%。接下来，福特 (F) 周二上涨 11.7%，此前该公司宣布将其首款电动皮卡 F-150 Lightning 的产量提高到每年 15 万辆。</blockquote></p><p>By that point in the week, General Motors stock (GM) was already up 12% in anticipation of its Chevy Silverado electric pickup truck unveiling, planned for Wednesday at the Consumer Electronics Show. But on the day of the announcement, shares slipped. Maybe investors were disappointed in the delivery timing, or maybe it was because the broad market tanked on signs that interest rates could rise sooner than expected.</p><p><blockquote>本周那个时候，通用汽车 (GM) 的股价已经上涨了 12%，预计其雪佛兰索罗德电动皮卡车将于周三在消费电子展上亮相。但在公告发布当天，股价下跌。也许投资者对交割时间感到失望，或者也许是因为大盘因利率可能比预期更早上升的迹象而下跌。</blockquote></p><p>What the Ford and Chevy pickups have in common is that they will target workers as well as suburban preeners in unblemished Carhartt jackets. Early versions will be priced around $40,000 and $100,000.</p><p><blockquote>福特和雪佛兰皮卡的共同点是，它们将瞄准穿着完美无瑕的卡哈特夹克的工人和郊区创业者。早期版本的价格将在4万美元和10万美元左右。</blockquote></p><p>The Chevy wins on electric specs—longer battery range and faster charging. But Ford wins on bringing its truck to market this spring. Chevy buyers will have to wait until spring 2023 for the cheaper truck and fall 2023 for the decked-out one. GM will also debut electric Chevy sport utility vehicles in 2023, including an Equinox that will start at $30,000.</p><p><blockquote>雪佛兰在电动规格上获胜——更长的电池续航里程和更快的充电速度。但福特在今年春天将其卡车推向市场方面取得了胜利。雪佛兰买家必须等到 2023 年春季才能买到更便宜的卡车，2023 年秋季才能买到装饰精美的卡车。通用汽车还将于 2023 年推出电动雪佛兰运动型多功能车，其中包括起售价为 30,000 美元的 Equinox。</blockquote></p><p>Pickup trucks could be the key to America’s electric-vehicle uptake. Last year, EVs hit an estimated 4% of total U.S. sales, up from 2%. But Europe and China are well ahead, with penetration rates in the low teens. Americans have so far had few electric choices for the types of vehicles they like to buy. Last year, the Ford F-150 led U.S. new-vehicle sales, as always. The only surprise was that the Ram 1500 pickup pulled ahead of the Chevy Silverado 1500 to be No. 2.</p><p><blockquote>皮卡车可能是美国电动汽车普及的关键。去年，电动汽车估计占美国总销量的 4%，高于 2%。但欧洲和中国遥遥领先，渗透率仅为十几岁。到目前为止，美国人对于他们喜欢购买的车辆类型几乎没有电动选择。去年，福特 F-150 一如既往地引领美国新车销量。唯一令人惊讶的是，Ram 1500 皮卡领先于雪佛兰索罗德 1500，位居第二。</blockquote></p><p>An electric Ram will take until 2024, according to owner Stellantis (STLA), a roll-up of American, Italian, and French brands. Start-up Rivian (RIVN) says it will ship electric pickups this year, but that stock slid 11% this past Wednesday after early backer Amazon.com (AMZN) said it’s putting in an order with Ram for delivery trucks. Tesla’s Cybertruck was expected last year, but has been delayed.</p><p><blockquote>据所有者 Stellantis (STLA) 称，电动 Ram 要到 2024 年才会问世，该公司是美国、意大利和法国品牌的综合体。初创公司Rivian（RIVN）表示，今年将出货电动皮卡，但上周三，在早期支持者亚马逊（AMZN）表示将向 Ram 订购送货卡车后，该公司股价下跌了 11%。特斯拉的 Cybertruck 去年就已上市，但已被推迟。</blockquote></p><p>Pent-up vehicle demand, meanwhile, suggests that a boom is coming. Amid shortages last year, U.S. light-vehicle sales were an estimated 15.1 million units, versus closer to 17 million a year before the pandemic. Average transaction prices have soared 30% from prepandemic levels, and incentives as a percentage of prices are at record lows.</p><p><blockquote>与此同时，被压抑的汽车需求表明繁荣即将到来。由于去年出现短缺，美国轻型汽车销量估计为 1510 万辆，而疫情爆发前每年接近 1700 万辆。平均交易价格已比大流行前的水平飙升了 30%，激励措施占价格的百分比也处于历史低位。</blockquote></p><p>This year, expect unit sales to rise only modestly, but by next year, when showrooms are full and pricing has eased, units could jump to 18 million, Credit Suisse says. EV penetration in the U.S. will double again this year to 8%, and top 50% by 2030, it adds.</p><p><blockquote>瑞士信贷表示，今年预计销量只会小幅增长，但到明年，当展厅爆满且定价放缓时，销量可能会跃升至 1800 万辆。它补充说，美国的电动汽车渗透率今年将再次翻一番，达到 8%，到 2030 年将达到 50%。</blockquote></p><p>One risk for legacy car makers is that they will run to stand still—that they must ramp up EV units with low profit margins for now to offset coming losses in high-margin gasoline models.</p><p><blockquote>传统汽车制造商面临的一个风险是，他们将停滞不前——他们目前必须增加利润率较低的电动汽车，以抵消高利润率汽油车型即将出现的损失。</blockquote></p><p>On the other hand, car makers could shift capacity from gasoline vehicles to electric ones ahead of customers’ willingness to make the switch. That could leave gas vehicles with high prices and profit margins, creating a long, lucrative “farewell tour,” as Morgan Stanley analyst Adam Jonas puts it.</p><p><blockquote>另一方面，汽车制造商可以在客户愿意转向电动汽车之前，将产能从汽油车转移到电动汽车。正如摩根士丹利（Morgan Stanley）分析师亚当-乔纳斯（Adam Jonas）所说，这可能会使汽油车的价格和利润率居高不下，从而造成一段漫长而利润丰厚的 “告别之旅”。</blockquote></p><p>Valuations appear undemanding. Ford goes for 12 times projected earnings, despite doubling in price last year. GM sells for nine times.</p><p><blockquote>估值似乎要求不高。尽管去年的价格翻了一番，但福特的盈利仍是预期的 12 倍。通用汽车的销量是原来的九倍。</blockquote></p><p>The bull case on Tesla is that it will do big things in both cars and adjacent markets. Philippe Houchois, who covers the stock for Jefferies, sees 35% upside from recent levels, to $1,400. Tesla lags behind legacy rivals on things like build quality and finish, but those are solvable problems, he says. It leads on software, batteries, and autonomy, which are durable advantages. He sees Tesla using software to extend the usefulness and profit potential of vehicles.</p><p><blockquote>特斯拉的看涨理由是，它将在汽车和邻近市场大展身手。杰富瑞 (Jefferies) 负责该股的 Philippe Houchois 认为，该股较近期水平上涨 35%，至 1,400 美元。他说，特斯拉在制造质量和表面处理等方面落后于传统竞争对手，但这些都是可以解决的问题。它在软件、电池和自主性方面处于领先地位，这些都是持久的优势。他认为特斯拉正在利用软件来扩展车辆的实用性和利润潜力。</blockquote></p><p>Most versions of the Tesla bear case assume that the company will do well in cars, but not well enough to justify a market value above $1 trillion. For example, J.P. Morgan’s Ryan Brinkman calls his price target of $295 “not ungenerous,” even though it implies a 70% stock plunge, because it values Tesla slightly ahead of world leader Toyota Motor (TM), despite producing a tenth as many cars for now.</p><p><blockquote>大多数版本的特斯拉贝尔案例都假设该公司在汽车领域会表现出色，但还不足以证明其超过 1 万亿美元的市值是合理的。例如，摩根大通（J.P. Morgan）的 Ryan Brinkman 评级，他将 295 美元的目标价定为 “并不慷慨”，尽管这意味着股价将暴跌 70%，因为特斯拉的估值略高于世界领先的丰田汽车（TM），尽管丰田汽车目前的产量只有丰田汽车的十分之一。</blockquote></p><p></p><p>Then there’s Gordon Johnson. He worked at large investment banks before starting GLJ Research, where he covers 20 stocks. He’s bullish on uranium stocks and bearish on cannabis, but all anyone wants to talk about, he says, is his $67 price target on Tesla. “I’ve gotten death threats,” he says. “Now I don’t even answer the phone when I have unknown calls.”</p><p><blockquote>然后是戈登-约翰逊。在开始 GLJ Research 之前，他曾在大型投资银行工作，在那里他研究了 20 只股票。他看好铀股，看跌大麻，但他说，大家只想谈论他对特斯拉的 67 美元目标价。“他说：”我收到了死亡威胁。“现在，当我有未知评级时，我甚至不接电话。”</blockquote></p><p>In Johnson’s view, there’s no reason to assume Tesla will do well in adjacent businesses. “You could take McDonald’s and say they’re going to start selling Nikes and chairs and pianos and add those valuations,” he says. In cars, he calculates that the stock price implies a production ramp-up that no car maker could achieve. “Selling cars is not selling iPhones or shirts,” he says.</p><p><blockquote>在约翰逊看来，没有理由认为特斯拉会在邻近业务中表现出色。“他说：”你可以拿麦当劳来说，他们将开始销售耐克鞋、椅子和钢琴，然后增加这些估值。在汽车方面，他计算出股价意味着任何汽车制造商都无法实现的产量增长。“他说：”卖车不是卖 iPhone 或衬衫。</blockquote></p><p>If Tesla’s three-year stock gain of nearly 1,400% has shaken Johnson’s confidence, it doesn’t show. After walking me through his valuation model, he said he’s concerned that his price target might be too high.</p><p><blockquote>如果说特斯拉三年内近 1400% 的股价涨幅动摇了约翰逊的信心，那么约翰逊的信心并没有显现出来。在向我介绍了他的估值模型后，他说他担心他的目标价可能太高。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/articles/tesla-ford-rivian-gm-stock-51641597012?mod=mw_quote_news\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","TSLA":"特斯拉","GM":"通用汽车","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.marketwatch.com/articles/tesla-ford-rivian-gm-stock-51641597012?mod=mw_quote_news","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1199490797","content_text":"Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the year. This, after some heady gains for the group last year.Predicting performance from here won’t be easy. I recently spoke with one analyst who says Tesla stock (ticker: TSLA) is headed to $1,400, and another who says $67. You know what they say: Sometimes you have to agree to disagree by a factor of 20.Tesla made the first big move, jumping 13.5% on Monday after the company reported fourth-quarter deliveries of 308,600 vehicles, trouncing estimates and its own record. Next, Ford (F) gained 11.7% on Tuesday after it announced that it would raise production of its first electric pickup, the F-150 Lightning, to 150,000 units a year.By that point in the week, General Motors stock (GM) was already up 12% in anticipation of its Chevy Silverado electric pickup truck unveiling, planned for Wednesday at the Consumer Electronics Show. But on the day of the announcement, shares slipped. Maybe investors were disappointed in the delivery timing, or maybe it was because the broad market tanked on signs that interest rates could rise sooner than expected.What the Ford and Chevy pickups have in common is that they will target workers as well as suburban preeners in unblemished Carhartt jackets. Early versions will be priced around $40,000 and $100,000.The Chevy wins on electric specs—longer battery range and faster charging. But Ford wins on bringing its truck to market this spring. Chevy buyers will have to wait until spring 2023 for the cheaper truck and fall 2023 for the decked-out one. GM will also debut electric Chevy sport utility vehicles in 2023, including an Equinox that will start at $30,000.Pickup trucks could be the key to America’s electric-vehicle uptake. Last year, EVs hit an estimated 4% of total U.S. sales, up from 2%. But Europe and China are well ahead, with penetration rates in the low teens. Americans have so far had few electric choices for the types of vehicles they like to buy. Last year, the Ford F-150 led U.S. new-vehicle sales, as always. The only surprise was that the Ram 1500 pickup pulled ahead of the Chevy Silverado 1500 to be No. 2.An electric Ram will take until 2024, according to owner Stellantis (STLA), a roll-up of American, Italian, and French brands. Start-up Rivian (RIVN) says it will ship electric pickups this year, but that stock slid 11% this past Wednesday after early backer Amazon.com (AMZN) said it’s putting in an order with Ram for delivery trucks. Tesla’s Cybertruck was expected last year, but has been delayed.Pent-up vehicle demand, meanwhile, suggests that a boom is coming. Amid shortages last year, U.S. light-vehicle sales were an estimated 15.1 million units, versus closer to 17 million a year before the pandemic. Average transaction prices have soared 30% from prepandemic levels, and incentives as a percentage of prices are at record lows.This year, expect unit sales to rise only modestly, but by next year, when showrooms are full and pricing has eased, units could jump to 18 million, Credit Suisse says. EV penetration in the U.S. will double again this year to 8%, and top 50% by 2030, it adds.One risk for legacy car makers is that they will run to stand still—that they must ramp up EV units with low profit margins for now to offset coming losses in high-margin gasoline models.On the other hand, car makers could shift capacity from gasoline vehicles to electric ones ahead of customers’ willingness to make the switch. That could leave gas vehicles with high prices and profit margins, creating a long, lucrative “farewell tour,” as Morgan Stanley analyst Adam Jonas puts it.Valuations appear undemanding. Ford goes for 12 times projected earnings, despite doubling in price last year. GM sells for nine times.The bull case on Tesla is that it will do big things in both cars and adjacent markets. Philippe Houchois, who covers the stock for Jefferies, sees 35% upside from recent levels, to $1,400. Tesla lags behind legacy rivals on things like build quality and finish, but those are solvable problems, he says. It leads on software, batteries, and autonomy, which are durable advantages. He sees Tesla using software to extend the usefulness and profit potential of vehicles.Most versions of the Tesla bear case assume that the company will do well in cars, but not well enough to justify a market value above $1 trillion. For example, J.P. Morgan’s Ryan Brinkman calls his price target of $295 “not ungenerous,” even though it implies a 70% stock plunge, because it values Tesla slightly ahead of world leader Toyota Motor (TM), despite producing a tenth as many cars for now.Then there’s Gordon Johnson. He worked at large investment banks before starting GLJ Research, where he covers 20 stocks. He’s bullish on uranium stocks and bearish on cannabis, but all anyone wants to talk about, he says, is his $67 price target on Tesla. “I’ve gotten death threats,” he says. “Now I don’t even answer the phone when I have unknown calls.”In Johnson’s view, there’s no reason to assume Tesla will do well in adjacent businesses. “You could take McDonald’s and say they’re going to start selling Nikes and chairs and pianos and add those valuations,” he says. In cars, he calculates that the stock price implies a production ramp-up that no car maker could achieve. “Selling cars is not selling iPhones or shirts,” he says.If Tesla’s three-year stock gain of nearly 1,400% has shaken Johnson’s confidence, it doesn’t show. After walking me through his valuation model, he said he’s concerned that his price target might be too high.","news_type":1,"symbols_score_info":{"GM":0.9,"RIVN":0.9,"F":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":5537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694043617,"gmtCreate":1641744434029,"gmtModify":1641744434241,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqqq","listText":"Qqqq","text":"Qqqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694043617","repostId":"1129882080","repostType":4,"repost":{"id":"1129882080","kind":"news","pubTimestamp":1641605937,"share":"https://www.laohunote.com/m/news/1129882080?lang=zh_CN&edition=full","pubTime":"2022-01-08 09:38","market":"us","language":"en","title":"The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年的前三次 IPO 都举步维艰。这就是原因。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129882080","media":"Barrons","summary":"The first initial public offerings of 2022, a trio of biotech companies, went public with dismal res","content":"<p><html><head></head><body>The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.</p><p><blockquote><html><head></head><body>三家生物技术公司于 2022 年首次公开募股上市，结果惨淡。</body></html></blockquote></p><p>Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.</p><p><blockquote>Amylyx Pharmaceuticals 和 Vigil Neuroscience 的股价均低于发行价，而 CinCor Pharma 则持平。首次公开募股市场的低迷表明，IPO市场尚未从2021年的低迷中恢复过来。</blockquote></p><p>The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.</p><p><blockquote>这三家公司是自去年 12 月新问题暂停以来首次进行交易的公司。2021 年经历了令人兴奋的 11 个月，IPO 创下了有史以来最好的一年，但通货膨胀和奥密克戎问题减缓了 12 月份的发行速度。当月只有十几家公司通过传统 IPO 上市，低于 11 月份的 34 家和 10 月份的 39 家。</blockquote></p><p>Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.</p><p><blockquote>Renaissance Capital 高级 IPO 策略师马特·肯尼迪 (Matt Kennedy) 表示，生物技术公司对整体市场趋势的敏感度较低，这使得它们能够继续前进，而其他公司则不然。</blockquote></p><p>The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.</p><p><blockquote>他说，周五三家公司首日表现平淡，是 2021 年 IPO 回报惨淡的延续。他说，在 2021 年使用传统 IPO 上市的 397 家公司中，大约 31%（即 121 家）的交易价格高于发行价。这意味着 69% 的股价低于 IPO 价格。</blockquote></p><p>The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.</p><p><blockquote>2021 届生物技术专业的表现更差。肯尼迪说，在去年上市的94家公司中，只有15家的交易价格高于发行价。他说，一些投资者仍然 “对流行抱有希望”，但目前对新交易的需求并不大。“他说：”在最初的投资者停止出现之前，只持续了很长时间，然后我们可能会看到活动暂停。</blockquote></p><p>A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he said.</p><p><blockquote>一个关键点可能会在下周到来，届时两笔备受瞩目的交易将开始。大型私募股权公司TPG和人力资源软件公司Justworks都计划进行交易。肯尼迪说，如果这些公司最终大幅削减价格范围，这将表明即使对于盈利的公司来说，IPO市场也充满挑战。“他说：”你不可能像 2021 年那样度过一年，然后在短短几周内就恢复正常。我们需要看到（最近 IPO）的回报率有所提高，然后才能期待正常的交易流动。</blockquote></p><p>Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.</p><p><blockquote>Cincor（股票代码：CINC）正在开发治疗高血压和其他心肾疾病的疗法，该公司于周五率先开业。Cincor 以 16 美元的价格出售 1210 万股股票，筹集了近 1.94 亿美元。该公司已申请发行 1100 万股股票，价格为 15 至 17 美元。股价开盘价为 21 美元，随后下跌，在收盘价之前，经常在 16 美元的 IPO 价格上下交易价格。</blockquote></p><p>Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.</p><p><blockquote>与此同时，Amylyx (AMLX) 的股价开盘价为 21 美元，收盘价为 18.07 美元，比发行价低近 5%。Amylyx专注于治疗ALS和其他神经退行性疾病的疗法。Amylyx 也扩大了交易规模，在以每股 19 美元的价格出售 1000 万股股票后筹集了 1.9 亿美元。该公司原计划以 18 至 20 美元的价格发行 875 万股。</blockquote></p><p>Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.</p><p><blockquote>Vigil (VIGL) 旨在为神经退行性疾病提供治疗，该公司以 14 美元的价格出售了 700 万股股票，筹集了 9800 万美元，低于 15 至 17 美元的价格范围。Vigil 开盘价为 12 美元，低于 IPO 价格，收盘下跌近 10%，至 12.65 美元。</blockquote></p><p>Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.</p><p><blockquote>乔丹·斯图尔特 (Jordan Stuart) 是 Federated Hermes Kaufmann funds 的市场策略师，该基金专注于小型、中型和大型市值公司并投资 IPO，他给投资者的建议只有一个：耐心。</blockquote></p><p>Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.</p><p><blockquote>斯图尔特说，许多生物技术公司在 2021 年很早就上市了，在投资之前等待 “时机催化剂 ”可能是有意义的。他指出了 Federated 在 2018 年上市的 Moderna（MRNA）方面的经验。斯图尔特说，Federated 放弃了购买 IPO，“因为没有什么紧急情况 ”促使他们进行投资。</blockquote></p><p>But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.</p><p><blockquote>但在2020年1月，疾病控制和预防中心（CDC）发现了美国首例新冠肺炎病例，到3月，全国各地的企业都在关闭，试图阻止病毒的传播。Stuart 表示，Federated 在 2020 年第一季度以每股 30 美元左右的价格投资了 Moderna。</blockquote></p><p>The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.</p><p><blockquote>同年 12 月晚些时候，该生物技术公司的 Covid-19 疫苗获得了美国食品和药物管理局的紧急使用授权。Moderna 的股价在 9 月份创下 384.86 美元的高点，目前交易价格为 213.58 美元。斯图尔特表示，截至 9 月 30 日，Federated 旗下基金持有 Moderna 的大量股份。</blockquote></p><p>While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.</p><p><blockquote>虽然投资经理可能通过等待留下了一些钱，但斯图尔特估计，Federated 的 Moderna 投资已经赚了 5 到 10 倍。“公司很早就上市是件好事。但考虑到去年 IPO 市场的火爆，耐心也是一种美德，”他说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年的前三次 IPO 都举步维艰。这就是原因。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年的前三次 IPO 都举步维艰。这就是原因。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2022-01-08 09:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.</p><p><blockquote><html><head></head><body>三家生物技术公司于 2022 年首次公开募股上市，结果惨淡。</body></html></blockquote></p><p>Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.</p><p><blockquote>Amylyx Pharmaceuticals 和 Vigil Neuroscience 的股价均低于发行价，而 CinCor Pharma 则持平。首次公开募股市场的低迷表明，IPO市场尚未从2021年的低迷中恢复过来。</blockquote></p><p>The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.</p><p><blockquote>这三家公司是自去年 12 月新问题暂停以来首次进行交易的公司。2021 年经历了令人兴奋的 11 个月，IPO 创下了有史以来最好的一年，但通货膨胀和奥密克戎问题减缓了 12 月份的发行速度。当月只有十几家公司通过传统 IPO 上市，低于 11 月份的 34 家和 10 月份的 39 家。</blockquote></p><p>Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.</p><p><blockquote>Renaissance Capital 高级 IPO 策略师马特·肯尼迪 (Matt Kennedy) 表示，生物技术公司对整体市场趋势的敏感度较低，这使得它们能够继续前进，而其他公司则不然。</blockquote></p><p>The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.</p><p><blockquote>他说，周五三家公司首日表现平淡，是 2021 年 IPO 回报惨淡的延续。他说，在 2021 年使用传统 IPO 上市的 397 家公司中，大约 31%（即 121 家）的交易价格高于发行价。这意味着 69% 的股价低于 IPO 价格。</blockquote></p><p>The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.</p><p><blockquote>2021 届生物技术专业的表现更差。肯尼迪说，在去年上市的94家公司中，只有15家的交易价格高于发行价。他说，一些投资者仍然 “对流行抱有希望”，但目前对新交易的需求并不大。“他说：”在最初的投资者停止出现之前，只持续了很长时间，然后我们可能会看到活动暂停。</blockquote></p><p>A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he said.</p><p><blockquote>一个关键点可能会在下周到来，届时两笔备受瞩目的交易将开始。大型私募股权公司TPG和人力资源软件公司Justworks都计划进行交易。肯尼迪说，如果这些公司最终大幅削减价格范围，这将表明即使对于盈利的公司来说，IPO市场也充满挑战。“他说：”你不可能像 2021 年那样度过一年，然后在短短几周内就恢复正常。我们需要看到（最近 IPO）的回报率有所提高，然后才能期待正常的交易流动。</blockquote></p><p>Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.</p><p><blockquote>Cincor（股票代码：CINC）正在开发治疗高血压和其他心肾疾病的疗法，该公司于周五率先开业。Cincor 以 16 美元的价格出售 1210 万股股票，筹集了近 1.94 亿美元。该公司已申请发行 1100 万股股票，价格为 15 至 17 美元。股价开盘价为 21 美元，随后下跌，在收盘价之前，经常在 16 美元的 IPO 价格上下交易价格。</blockquote></p><p>Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.</p><p><blockquote>与此同时，Amylyx (AMLX) 的股价开盘价为 21 美元，收盘价为 18.07 美元，比发行价低近 5%。Amylyx专注于治疗ALS和其他神经退行性疾病的疗法。Amylyx 也扩大了交易规模，在以每股 19 美元的价格出售 1000 万股股票后筹集了 1.9 亿美元。该公司原计划以 18 至 20 美元的价格发行 875 万股。</blockquote></p><p>Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.</p><p><blockquote>Vigil (VIGL) 旨在为神经退行性疾病提供治疗，该公司以 14 美元的价格出售了 700 万股股票，筹集了 9800 万美元，低于 15 至 17 美元的价格范围。Vigil 开盘价为 12 美元，低于 IPO 价格，收盘下跌近 10%，至 12.65 美元。</blockquote></p><p>Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.</p><p><blockquote>乔丹·斯图尔特 (Jordan Stuart) 是 Federated Hermes Kaufmann funds 的市场策略师，该基金专注于小型、中型和大型市值公司并投资 IPO，他给投资者的建议只有一个：耐心。</blockquote></p><p>Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.</p><p><blockquote>斯图尔特说，许多生物技术公司在 2021 年很早就上市了，在投资之前等待 “时机催化剂 ”可能是有意义的。他指出了 Federated 在 2018 年上市的 Moderna（MRNA）方面的经验。斯图尔特说，Federated 放弃了购买 IPO，“因为没有什么紧急情况 ”促使他们进行投资。</blockquote></p><p>But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.</p><p><blockquote>但在2020年1月，疾病控制和预防中心（CDC）发现了美国首例新冠肺炎病例，到3月，全国各地的企业都在关闭，试图阻止病毒的传播。Stuart 表示，Federated 在 2020 年第一季度以每股 30 美元左右的价格投资了 Moderna。</blockquote></p><p>The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.</p><p><blockquote>同年 12 月晚些时候，该生物技术公司的 Covid-19 疫苗获得了美国食品和药物管理局的紧急使用授权。Moderna 的股价在 9 月份创下 384.86 美元的高点，目前交易价格为 213.58 美元。斯图尔特表示，截至 9 月 30 日，Federated 旗下基金持有 Moderna 的大量股份。</blockquote></p><p>While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.</p><p><blockquote>虽然投资经理可能通过等待留下了一些钱，但斯图尔特估计，Federated 的 Moderna 投资已经赚了 5 到 10 倍。“公司很早就上市是件好事。但考虑到去年 IPO 市场的火爆，耐心也是一种美德，”他说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/2022-ipos-fall-weak-51641580444?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc.","AMLX":"Amylyx Pharmaceuticals"},"source_url":"https://www.barrons.com/articles/2022-ipos-fall-weak-51641580444?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129882080","content_text":"The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he said.Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.","news_type":1,"symbols_score_info":{"AMLX":0.9,"CINC":0.9,"VIGL":0.9}},"isVote":1,"tweetType":1,"viewCount":3703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695775599,"gmtCreate":1641639144236,"gmtModify":1641639144846,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"themes":[],"title":"","htmlText":"Qqq","listText":"Qqq","text":"Qqq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/695775599","repostId":"2201243576","repostType":4,"isVote":1,"tweetType":1,"viewCount":3867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}